Day: June 8, 2023

BOREO PLC        INVESTOR NEWS     8 June 2023 at 09:00 EET Boreo acquires health technology company Delfin Technologies Boreo Plc has on June 8, 2023 signed a share purchase agreement to acquire the entire share capital of Delfin Technologies Oy (“Delfin Technologies”, “Delfin” or “the Company”), from Tapani Lahtinen, the Company’s CEO Jouni Nuutinen and a group of private shareholders (“Sellers”). The Company will continue operating after the transaction as part of Boreo’s Electronics Business Area, led by Jouni Nuutinen. “We are delighted to have been provided the opportunity to acquire Delfin Technologies and to partner with the management in the Company’s growth journey. Delfin Technologies is a company led by great people and has a track record of consistently generating high margins and strong returns on capital. Through its attractive...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGeneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company’s offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland. The agenda of the meeting will be as follows: 1      Approval of the Management Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2022 The Board of Directors proposes that the management report, the statutory financial statements and the consolidated financial statements of ObsEva SA for fiscal year 2022 be approved. 2      Discharge of Liability for...

Moody’s Investors Service affirmed the credit rating of Coop Pank AS. Investment grade credit rating with a stable outlook was affirmed at the same level as year ago. According to Paavo Truu, CFO of Coop Pank, the confirmation of the credit rating at the current level confirms that the bank has been able to maintain a high quality of the loan portfolio even in difficult times and has shown good profitability. “The confirmation of the rating and stable outlook gives private individuals and businesses additional confidence to become a customer of Coop Pank and keep their money in a domestic financial institution,” said Truu. Ratings affirmed by Moody’s Investors Service for Coop Pank AS:Foreign- and local currency long- and short-term bank deposit rating Baa2/Prime-2 Long- and short-term counterparty risk assessment...

PRESS RELEASE REGULATED INFORMATION 8 June 2023, 7:00 CEST Disclosure of transparency notification Mechelen, Belgium, 8 June 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous provisions (the “Belgian Transparency Act”), that on 6 June 2023 it received a transparency notification dated 1 June 2023 indicating that on 25 May 2023 the aggregate number of voting rights and equivalent financial instruments held by Heights Capital Management, Inc. (through CVI Investments, Inc.) decreased below the 3% notification threshold. The...

OSLO, Norway (8 June 2023) – TGS, a global provider of energy data and intelligence, in a strategic collaboration with SLB, today announced the start of the Engagement 4 Ocean Bottom Node (OBN) multi-client acquisition in the U.S. Gulf of Mexico. Acquisition of the 152 OCS block, sparse OBN survey is now underway, extending contiguous data coverage from prior phases into western Green Canyon. In an area known for increasingly challenging subsurface imaging, application of full-waveform inversion (FWI) utilizing ultra-long offsets will provide a dataset that represents a step-change in the conceivable geological and geophysical interpretation. In support of existing leases and future lease sale acreage, fast-track products will be made available in Q4 2023, with final processing completion scheduled for H2 2024. Kristian Johansen, CEO...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it has entered into a manufacturing alliance with NorthX Biologics AB (“NorthX”). NorthX is a Contract Development and Manufacturing Organization (CDMO) and serves as the National Swedish Innovation Hub for the GMP manufacture of biologics used in vaccines, gene therapy and other advanced therapy medicinal products (ATMPs). Mendus and NorthX will co-establish cell therapy manufacturing capabilities in Sweden, which will be used for late-stage development and commercial manufacturing of Mendus’ lead asset vididencel. In conjunction with the NorthX collaboration, Mendus has entered into an agreement with Flerie Invest AB (“Flerie”), a leading Swedish investment firm. Flerie will initially invest SEK...

Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit€1.8 million research tax credit received on June 7, 2023, to extend runway to the end of September 2023 Lloyd Diamond participates at the Octane Ophthalmology Tech Forum Edison published an updated analyst report  Paris, France, June 8, 2023 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that it has received a € 1.8 million Research Tax Credit. This cash injection will help extend the company’s cash runway until the end of September 2023, providing more flexibility to pursue its longer-term funding needs to support its strategic...

8 June 2023 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM receives request for an EGM from a shareholderRock Investment SAS requests an EGM to change the board and the articles This request does not constitute an offer to GAM shareholders The GAM Board continues to strongly recommend that shareholders accept the Liontrust proposal as supported by the GAM Portfolio ManagersLate on the evening of 7 June 2023, GAM Holding AG received a request from Rock Investment SAS (part of the investor group comprised of Newgame SA and Bruellan SA) who holds 5.11% of GAM shares to hold an extraordinary general meeting (EGM) of shareholders on or about 16 August 2023. This would be subsequent to the results of the Liontrust tender offer being known, based on the current timeline.  The proposed EGM would contemplate the...

Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid termEuropean champion committed to further extending global leadership in attractive and growing generics and biosimilars market, via purpose-driven strategy with focus on access and sustainabilitySix strategic levers to drive long-term investor value; attractive financial outlook, including targeted investment grade credit profile and progressive dividend policyNew York, June 8, 2023 — Sandoz today hosts the first of two Capital Markets Days (CMDs) for investors, in New York City, to set out its plans for growth and success as a standalone company, following the proposed 100% spin-off from Novartis. Sandoz reported sales of USD 9.1 bn in 2022, with a record of six consecutive...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling USD 26.25 million to Basilea. David Veitch, Chief Executive Officer of Basilea, said: “These sales milestone events confirm that Cresemba continues to serve a medical need in patients suffering from life-threatening invasive mold infections in many countries across the globe.” Based on the license agreement between Basilea and Pfizer, Basilea...